Table 1.
Marker | Non-metastatic sCRC (n = 26) | Metastatic sCRC (n = 25) | p | Total (n = 51) |
---|---|---|---|---|
MLH1 | ||||
Loss | 5 (20%) | 0 (0%) | 0.050 | 5 (10%) |
Normal | 20 (80%) | 25 (100%) | 45 (90%) | |
Excluded | 1 | 0 | 1 | |
PMS2 | ||||
Loss | 6 (25%) | 0 (0%) | 0.020 | 6 (14%) |
Normal | 18 (75%) | 18 (100%) | 36 (86%) | |
Excluded | 2 | 7 | 9 | |
MSH2 | ||||
Loss | 2 (8%) | 0 (0%) | NS | 2 (4%) |
Normal | 22 (92%) | 23 (100%) | 45 (96%) | |
Excluded | 1 | 2 | 3 | |
MSH6 | ||||
Loss | 2 (8%) | 0 (0%) | NS | 2 (4%) |
Normal | 23 (92%) | 24 (100%) | 47 (96%) | |
Excluded | 1 | 1 | 2 | |
c-Myc | ||||
<10% | 2 (8%) | 7 (29%) | NS | 9 (19%) |
≥10% | 22 (92%) | 17 (71%) | 39 (81%) | |
Excluded | 2 | 1 | 3 | |
Her2 | ||||
0/1+ | 26 (100%) | 23 (96%) | NS | 49 (98%) |
2+ | 0 (0%) | 0 (0%) | 0 (0%) | |
3+ | 0 (0%) | 1 (4%) | 1 (2%) | |
Excluded | 0 | 1 | 1 | |
p53 | ||||
0 | 6 (23%) | 7 (29%) | NS | 13 (26%) |
<10% | 9 (35%) | 6 (35%) | 15 (30%) | |
≥10% | 11(42%) | 11 (46%) | 22 (44%) | |
Excluded | 0 | 1 | 1 | |
β-catenin | ||||
Negative | 18 (69%) | 11 (46%) | NS | 29 (58%) |
Positive | 8 (31%) | 13 (54%) | 21 (42%) | |
Excluded | 0 | 1 | 1 | |
CEA | ||||
Negative | 11 (22%) | 0 (0%) | <0.001 | 11 (22%) |
Positive | 15 (88%) | 24 (100%) | 39 (78%) | |
EGFR | ||||
0 | 16 (62%) | 5 (21%) | <0.001 | 21 (42%) |
1–10% | 4 (15%) | 1 (4%) | 5 (10%) | |
10–35% | 6 (23%) | 4 (17%) | 10 (20%) | |
>35% | 0 | 14 (58%) | 14 (28%) | |
Excluded | 0 | 1 | 1 | |
Ki-67 | ||||
<50% | 15 (58%) | 19 (83%) | NS | 34 (69%) |
≥50% | 11 (42%) | 4 (17%) | 15 (31%) | |
Excluded | 0 | 2 | 2 |
Results expressed as number of cases (percentage); CEA: carcinoembryogenic antigen; NS: no statistically significant differences found between groups (p > 0.05). Cases excluded due to technical problems were not considered in the statistical analysis.